251 related articles for article (PubMed ID: 22484424)
21. Cellular stress in xenopus kidney cells enhances the phosphorylation of eukaryotic translation initiation factor (eIF)4E and the association of eIF4F with poly(A)-binding protein.
Fraser CS; Pain VM; Morley SJ
Biochem J; 1999 Sep; 342 Pt 3(Pt 3):519-26. PubMed ID: 10477262
[TBL] [Abstract][Full Text] [Related]
22. Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.
Jin S; Chang IH; Kim JW; Whang YM; Kim HJ; Hong SA; Lee TJ
J Korean Med Sci; 2017 Aug; 32(8):1327-1336. PubMed ID: 28665070
[TBL] [Abstract][Full Text] [Related]
23. Tumor suppression by small molecule inhibitors of translation initiation.
Chen L; Aktas BH; Wang Y; He X; Sahoo R; Zhang N; Denoyelle S; Kabha E; Yang H; Freedman RY; Supko JG; Chorev M; Wagner G; Halperin JA
Oncotarget; 2012 Aug; 3(8):869-81. PubMed ID: 22935625
[TBL] [Abstract][Full Text] [Related]
24. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
[TBL] [Abstract][Full Text] [Related]
25. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract][Full Text] [Related]
26. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.
Fingar DC; Richardson CJ; Tee AR; Cheatham L; Tsou C; Blenis J
Mol Cell Biol; 2004 Jan; 24(1):200-16. PubMed ID: 14673156
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
[TBL] [Abstract][Full Text] [Related]
28. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
Li G; Shan C; Liu L; Zhou T; Zhou J; Hu X; Chen Y; Cui H; Gao N
PLoS One; 2015; 10(2):e0117440. PubMed ID: 25659153
[TBL] [Abstract][Full Text] [Related]
29. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
[TBL] [Abstract][Full Text] [Related]
31. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
Guo B; Zhang Y; Luo G; Li L; Zhang J
Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
33. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
Dumstorf CA; Konicek BW; McNulty AM; Parsons SH; Furic L; Sonenberg N; Graff JR
Mol Cancer Ther; 2010 Dec; 9(12):3158-63. PubMed ID: 20971826
[TBL] [Abstract][Full Text] [Related]
34. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
[TBL] [Abstract][Full Text] [Related]
35. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
36. Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells.
Frosi Y; Ramlan SR; Brown CJ
J Vis Exp; 2020 May; (159):. PubMed ID: 32421011
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of eIF4F complex loading inhibits the survival of malignant glioma.
Dong QF; Yan ZF; Li PQ; Yang X; Huo JL; Zhen HN
Oncol Rep; 2018 Oct; 40(4):2399-2407. PubMed ID: 30066885
[TBL] [Abstract][Full Text] [Related]
39. Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells.
Pola C; Formenti SC; Schneider RJ
Cancer Res; 2013 Jul; 73(14):4571-8. PubMed ID: 23722547
[TBL] [Abstract][Full Text] [Related]
40. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo.
Cao XX; Xu JD; Xu JW; Liu XL; Cheng YY; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
Breast Cancer Res Treat; 2010 Sep; 123(2):375-86. PubMed ID: 19946739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
